The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai

Today, the world’s leading cancer specialist, Royal Marsden NHS Foundation Trust, has announced a partnership with two AI superpowers, NTT DATA and CARPL.ai. The plan is to work closely in the collaboration to design the advanced radiology analysis service for cancer powered by the strong AI models.

NTT DATA is the global digital business and technology leader, whereas CARPL.ai is the leading AI imaging enterprise. All of them will develop and design the AI medical imaging, transforming the research to improve the patient outcomes and diagnose the problem at an early stage, the only way to prevent diseases like cancer.

The organization is confident that the new partnership will open new doors in the clinical analysis of cancer and is a milestone in involving AI in cancer medication innovation. The foundation is one of the world’s most advanced cancer treatment and research centers.

About NTT DATA and CARPL.ai

NTT DATA is a Japanese multinational company providing information technology services. The headquarters of this Japanese company is in Tokyo, Japan. The company has developed an MLOps clinical imaging platform that is making it an ideal choice for the mission of the Royal Marsden NHS Foundation Trust.

The platform is handled through the bespoke AI computing solution with the available high-duty Dell servers. To handle the process, the latest GPU systems are used by CARPL.ai, helping to manage the large sets of radiology AI models and to manage the AI algorithms.

Another help from NTT DATA is its specialist imaging AI consulting services; therefore, it will help the foundation to evaluate the AI tools for the clinical studies and analysis.

Professor Dow-Mu Koh is a well-known personality working as a Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden

AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely. By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.

How AI is the Power of NTT DATA and CARPLE.ai to Win the Deal

AI is the power behind every successful system nowadays, making them more efficient and advanced. NTT DATA has more power in this regard, but CARPL.ai has the power to run the remarkable AI algorithms of NTT DATA. On this, Professor Mike Lewis, who is the NIHR Scientific Director for Innovation say,

This AI-powered service represents the cutting edge of cancer research, and it is going to transform treatment, better support NHS staff, and ultimately change patients’ lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it

Similarly, the AI feature integration company, Weborik Hub, is representing the best services to include AI features in web solutions.

Once the services are live by NTT DATA and CARPL.ai, The Royal Marsden will be able to evaluate multiple critical insights for the AI models for several cancer types. This is surely a great step towards the advancement of cancer treatment.